Stock Market & Financial Investment News

News Breaks September 27, 2012 08:36 EDT BSX Boston Scientific launches Emerge PTCA balloon dilatation catheter in U.S. Boston Scientific has received U.S. Food and Drug Administration clearance for the Emerge Percutaneous Transluminal Coronary Angioplasty Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter has been commercially available in CE Mark countries since earlier this year. News For BSX From The Last 14 Days Check below for free stories on BSX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 12:22 EDT BSX Boston Scientific says new data shows blood pressure reduction with Vessix Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. 10:44 EDT BSX Boston Scientific says Lotus system met primary performance endpoint in trial Subscribe for More Information 09:35 EDT BSX Boston Scientific says trials show 'exceptional' safety, efficacy data on stents Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." May 21, 2013 11:49 EDT BSX Boston Scientific data show Bronchial Thermoplasty benefits for up to five years Subscribe for More Information 05:48 EDT BSX OrbusNeich seizes Boston Scientific stents as part of patent infringement case Subscribe for More Information May 20, 2013 09:41 EDT BSX Supreme Court agrees to hear Medtronic-Boston Scientific patent case Reported by SCOTUSblog live blog of court orders and opinions. May 16, 2013 16:13 EDT BSX Vascular Solutions files patent infringement complaint against Boston Scientific Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. 07:51 EDT BSX Boston Scientific price target raised to $12 from $9 at JMP Securities JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. 07:28 EDT BSX I/O Central to host a conference Subscribe for More Information May 14, 2013 15:33 EDT BSX Boston Scientific has a conference call hosted by JPMorgan JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. May 10, 2013 10:00 EDT BSX On The Fly: Analyst Upgrade Summary Subscribe for More Information 09:03 EDT BSX Boston Scientific receives CEO Mark approval for Rhythmia mapping system Subscribe for More Information 05:46 EDT BSX Boston Scientific upgraded to Outperform from Market Perform at Wells Fargo Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.